AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8299548
Drug: Monoamine oxidase
RxNorm normalized name: Monoamine oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoamine oxidase inhibitor (MAOI) phenelzine
Trial: 8299548
Drug: Tricyclic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic therapy
Trial: 2936958
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or alternative treatment
Trial: 31036033
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (moist hot pack, soft tissue mobilization, manual therapy, therapeutic exercise)
Trial: 25926725
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g leucine/day plus resistance training (leucine group [LG], n=15)
Trial: 12600870
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous amino acid solution (without glutamine)
Trial: 1537959
Drug: Methylphenidate (35.21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (35.21 mg/day)
Trial: 6726596
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplements from the 16th week of amenorrhea until 6 weeks post partum
Trial: 29659116
Drug: DC0120 (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC0120 (5% minoxidil formulation), applied twice per day for 16 weeks
Trial: 29659116
Drug: Comparator (ALOSTIL®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (ALOSTIL® minoxidil product), applied twice per day for 16 weeks
Trial: 29659116
Drug: DC0120 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC0120 and Comparator (both minoxidil treatments)
Trial: 27572136
Drug: Intravenous methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous methadone (0.1-0.125 mg/kg) in addition to standard care
Trial: 21337116
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment for 1 month
Trial: 18614738
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (4 capsules of 1g providing 2.7g n-3 PUFAs per day)
Trial: 18614738
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (4 capsules of 1g per day)
Trial: 18614738
Drug: No oil
RxNorm normalized name: oregano oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oil capsules
Trial: 10235530
Drug: IGF-1/IGFBP-3 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF-1/IGFBP-3 treatment at 1.0 mg/kg/day
Trial: 10235530
Drug: IGF-1/IGFBP-3 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF-1/IGFBP-3 treatment at 2.0 mg/kg/day
Trial: 10235530
Drug: IGF-1/IGFBP-3 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF-1/IGFBP-3 treatment at 4.0 mg/kg/day
Trial: 10235530
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IGF-1/IGFBP-3 treatment)
Trial: 8904257
Drug: Vecuronium 0.056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.056 mg/kg
Trial: 8904257
Drug: Vecuronium 0.14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.14 mg/kg
Trial: 8904257
Drug: Vecuronium 0.28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.28 mg/kg
Trial: 8904257
Drug: Atracurium 0.28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.28 mg/kg
Trial: 1824542
Drug: Casein formula
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein formula (1.4 gm protein/100 ml)
Trial: 1824542
Drug: Supplemented human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplemented human milk (1.4 gm protein/100 ml)
Trial: 6405766
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine hydrochloride 0.4 mg with isobaric 0.5% bupivacaine
Trial: 6405766
Drug: Morphine 0.2
RxNorm normalized name: morphine 0.23 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.2 mg (older patients only)
Trial: 26297132
Drug: Ingested 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingested 0.3 g of raw salmon
Trial: 26297132
Drug: Ingested 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingested 30 g of raw salmon
Trial: 22595107
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL of 2% lidocaine with 1:200,000 epinephrine
Trial: 22595107
Drug: 3.6 mL
RxNorm normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mL of 2% lidocaine with 1:200,000 epinephrine
Trial: 15509514
Drug: AdvHSV‐tk gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdvHSV‐tk gene therapy (3 x 10(10) pfu) followed by intravenous ganciclovir (GCV), 5 mg/kg twice daily for 14 days
Trial: 9322826
Drug: nifedipine-capsules (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine-capsules (10 mg)
Trial: 9322826
Drug: captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: captopril (25 mg)
Trial: 9322826
Drug: nifedipine-retard (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine-retard (20 mg)
Trial: 31770598
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (APDT)
Trial: 29049902
Drug: Concurrent Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Treatment with Prolonged Exposure (COPE)
Trial: 26769459
Drug: Rasagiline 1
RxNorm normalized name: rasagiline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 1 mg daily for 12 weeks
Trial: 23442834
Drug: 72 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 72 weeks of treatment
Trial: 23442834
Drug: 48 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 weeks of treatment
Trial: 23442834
Drug: Stopping treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping treatment at week 12 for non-cEVR patients
Trial: 23442834
Drug: Stopping treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping treatment at week 12 for cEVR patients
Trial: 18647396
Drug: Remote therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote therapy (telephone, internet, videoconference)
Trial: 16834839
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 40 000 U weekly (QW)
Trial: 10693734
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of orlistat TID
Trial: 10693734
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of orlistat TID
Trial: 9490144
Drug: Leuprolide 3.75
RxNorm normalized name: leuprolide 3.75 mg intramuscular powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide 3.75 mg LP
Trial: 9490144
Drug: Triptorelin 3.75
RxNorm normalized name: triptorelin 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 3.75 mg LP
Trial: 3754233
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg bd + Pirenzepine 50 mg bd
Trial: 3754233
Drug: Pirenzepine 50
RxNorm normalized name: pirenzepine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 50 mg bd
Trial: 3754233
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg bd + Pirenzepine 25 mg bd
Trial: 27342387
Drug: Therapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose of tedizolid phosphate (200mg)
Trial: 27342387
Drug: Supratherapeutic dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supratherapeutic dose of tedizolid phosphate (1200mg)
Trial: 12516414
Drug: Indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 mg three times a day for 7 days with tegafur 200 mg three times a day (Group I, n = 11)
Trial: 12516414
Drug: Tegafur 200
RxNorm normalized name: tegafur 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegafur 200 mg three times a day without indomethacin (Group II, n = 10)
Trial: 9098853
Drug: Allopurinol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (10 mg/kg after meeting criteria and before cannulation, plus a 20 mg/kg priming dose to the ECMO circuit)
Trial: 8210924
Drug: Etodolac (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac (300 mg b.i.d.)
Trial: 8210924
Drug: Active-reference preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active-reference preparations (including piroxicam, naproxen, indomethacin, indomethacin SR, diclofenac SR)
Trial: 8210924
Drug: Active-reference preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active-reference preparations and placebos
Trial: 3093661
Drug: Lactose-free preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-free preparation
Trial: 28514624
Drug: Evacetrapib (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib (130 mg daily)
Trial: 23135693
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tropisetron alone (T)
Trial: 23135693
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tropisetron and 8 mg dexamethasone (TD)
Trial: 23135693
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tropisetron and 40 mg methylprednisolone (TM)
Trial: 21542721
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (300,000 IU/month intramuscular injection for 6 months)
Trial: 21542721
Drug: Placebo (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intramuscular injection for 6 months)
Trial: 18498678
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate 200 mcg once-daily for 8 days
Trial: 17205817
Drug: Three-step sequential
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-step sequential method (TSSM) plus inhalation of Pulmicort Turbuhaler 200 microg, twice a day
Trial: 8694043
Drug: Misoprostol every
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol every 3 hours (maximum of 8 doses)
Trial: 8694043
Drug: Misoprostol every
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol every 6 hours (maximum of 4 doses)
Trial: 27696720
Drug: FeFol (iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FeFol (iron and folic acid tablet)
Trial: 27696720
Drug: MMN (multiple-micronutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMN (multiple-micronutrients tablet)
Trial: 27696720
Drug: PE (protein-energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE (protein-energy lipid-based nutritional supplement)
Trial: 27696720
Drug: PE +
RxNorm normalized name: Chlorpheniramine Maleate/Phenylephrine Hydrochloride 4 MG-10 MG Oral Tablet [SINUS PE + ALLERGY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE + MMN (protein-energy + multiple-micronutrients lipid-based nutritional supplement)
Trial: 25837705
Drug: Testosterone administration
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone administration (2 mg/kg testosterone enanthate monthly for two months before surgery)
Trial: 17540191
Drug: Nurse-administered tailored
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered tailored behavioral intervention
Trial: 17540191
Drug: Nurse-administered medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered medication management
Trial: 17540191
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tailored behavioral intervention and medication management
Trial: 11451215
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (OM) 10 mg once daily
Trial: 7747848
Drug: Propofol (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (median dose 3.1 mg.kg‐1)
Trial: 7747848
Drug: Thiopentone (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (median dose 6.0 mg.kg‐1)
Trial: 7747848
Drug: Intralipid 10%
RxNorm normalized name: Intralipid 10% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid 10% 0.3 ml.kg‐1
Trial: 299451
Drug: butorphanol/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: butorphanol/acetaminophen
Trial: 299451
Drug: oxycodone/acetaminophen
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxycodone/acetaminophen
Trial: 28376743
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg FLU-v in saline (arm 1)
Trial: 28376743
Drug: Emulsified 500
RxNorm normalized name: diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emulsified 500 μg FLU-v in Montanide ISA-51 and WFI followed by one saline dose (arm 2)
Trial: 28376743
Drug: Montanide ISA-51
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montanide ISA-51 and WFI emulsion followed by one saline dose (arm 4)
Trial: 28376743
Drug: Two saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two saline doses (arm 3)
Trial: 25983095
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with docetaxel and capecitabine
Trial: 20631375
Drug: Romiplostim 500
RxNorm normalized name: ROMIPLOSTIM 500MCG/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romiplostim 500 μg
Trial: 17952697
Drug: Water exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water exercise once-weekly for 24 weeks
Trial: 17952697
Drug: Water exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water exercise twice-weekly for 24 weeks
Trial: 15602503
Drug: Nalbuphine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (5 mg/70 kg, intravenous)
Trial: 15602503
Drug: Nalbuphine+cocaine (combination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine+cocaine (combination)
Trial: 15602503
Drug: Cocaine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (0.2 mg/kg, intravenous)
Trial: 7700752
Drug: DTP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP and PRP-T in one injection (Group 1)
Trial: 2505632
Drug: Flumazenil 4
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil 4 mg
Trial: 24824770
Drug: Methylphenidate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate treatment + 6‐wk exercise (sports‐ADHD)
Trial: 24824770
Drug: Methylphenidate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate treatment + 6‐wk education (edu‐ADHD)
Trial: 23463297
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's Wort (SJW) 300 mg × 3/day for 2 weeks after PCI
Trial: 20078381
Drug: 0.04% retinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04% retinol cream
Trial: 16278692
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (PJ) supplementation (400 ml daily for 5 weeks)
Trial: 16278692
Drug: Placebo (synthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (synthetic orange‐flavoured drink, 400 ml daily for 5 weeks)
Trial: 11481130
Drug: Cognitive/Behavioral Therapy-Alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive/Behavioral Therapy-Alone (CBT)
Trial: 9233238
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of essential fatty acids (EFA) - 20 ml solution A (1.6 gr EFA with linoleic acid, 112 UI vitamin A, 5 UI Vitamin E) applied every 8 hours for 21 days
Trial: 9233238
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of mineral oil - 20 ml solution B (1.6 gr mineral oil, 112 UI Vitamin A, 5 UI Vitamin E) applied every 8 hours for 21 days
Trial: 5320590
Drug: Chronic chlorpromazine
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic chlorpromazine (CPZ) administration
Trial: 30753377
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of azathioprine with adalimumab
Trial: 23128963
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen 10 mg/kg within 12‐24 h after birth followed by 5 mg/kg at 24 and 48 h
Trial: 23128963
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ibuprofen treatment)
Trial: 16965418
Drug: Placebo (cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cream base formulation)
Trial: 19629020
Drug: Atypical antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotic medications
Trial: 9240877
Drug: L-thyroxine (LT4)
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-thyroxine (LT4) replacement therapy
Trial: 7506175
Drug: Nimesulide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (5 mg/kg/day)
Trial: 7506175
Drug: Paracetamol (26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (26 mg/kg/day)
Trial: 30300371
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention (medication adjustment, stepped mental health care, exercise therapy)
Trial: 28665259
Drug: Lenvatinib (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (24 mg/day; 28-day cycle)
Trial: 26610844
Drug: Tafenoquine regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine regimen with three daily loading doses plus weekly maintenance at 200‐mg for 10 weeks or longer
Trial: 26610844
Drug: Tafenoquine 200‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 200‐mg weekly
Trial: 26610844
Drug: Mefloquine 250‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 250‐mg weekly
Trial: 26610844
Drug: Tafenoquine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine with a three‐day loading dose at 400‐mg
Trial: 26610844
Drug: Tafenoquine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine with a three‐day loading dose at 400‐mg without follow-up weekly maintenance doses
Trial: 24282608
Drug: Cochlear Implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear Implant (CI) before 5 years of age
Trial: 24282608
Drug: Cochlear Implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear Implant (CI) after 5 years of age
Trial: 24282608
Drug: Cochlear Implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear Implant (CI) with more than 5 years of implant use
Trial: 24282608
Drug: Cochlear Implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear Implant (CI) regardless of age at implantation
Trial: 18343056
Drug: Testosterone supplementation
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone supplementation in combination with hormone replacement therapy
Trial: 18343056
Drug: Conventional postmenopausal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional postmenopausal hormone therapy
Trial: 10971167
Drug: Cisplatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (20 mg/m(2)), Ifosfamide (1.5 g/m(2)), Irinotecan (60 mg/m(2)) with rhG-CSF support
Trial: 10971167
Drug: Cisplatin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (15 mg/m(2)), Irinotecan (50 mg/m(2)) with rhG-CSF support (after dose adjustment)